Program
Celecoxib
Also written as “celecoxib”, “Celecoxib 200mg” and “Celecoxib + Acetaminophen”.
Its studies are mostly in Osteoarthritis · Osteoarthritis, Knee · Low Back Pain · Migraine Disorders · Pain, Postoperative, led by 16 companies.
Drug pageCelecoxib: every studyMany companies study it; this page follows only the 66 they lead. All 383 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatrisits history only | 320 open or running | phase 4since Aug 26, 2005 | Aug 26, 2005 | none ahead |
| Pfizerits history only | 100 open or running | phase 4since Sep 9, 2005 | May 8, 2002 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 40 open or running | phase 2since Jun 8, 2015 | Jun 8, 2015 | none ahead |
| NeuroSense Therapeuticsits history only | 40 open or running | phase 2since Nov 13, 2019 | Aug 29, 2019 | none ahead |
| Leidos Life Sciences | 30 open or running | phase 2since Oct 7, 2021 | Oct 7, 2021 | none ahead |
| BioDelivery Sciences Internationalits history only | 20 open or running | phase 3since Dec 27, 2016 | Dec 27, 2016 | none ahead |
| Laboratorios Silanes S.A. de C.V.its history only | 20 open or running | phase 3since Jun 26, 2024 | Jun 26, 2024 | none ahead |
| Aralez Pharmaceuticalsits history only | 10 open or running | phase 1since Aug 5, 2008 | Aug 5, 2008 | none ahead |
| Arthritis Innovationits history only | 10 open or running | phase 2since May 8, 2018 | May 8, 2018 | none ahead |
| Astellas Pharmaits history only | 10 open or running | phase 3since May 5, 2010 | May 5, 2010 | none ahead |
| Bausch Health Companiesits history only | 10 open or running | phase 3since Jul 3, 2006 | Jul 3, 2006 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 10 open or running | phase 4since Feb 3, 2017 | Feb 3, 2017 | none ahead |
| Dong-A STits history only | 10 open or running | phase 4since May 19, 2016 | May 19, 2016 | none ahead |
| Kitov Pharmaceuticalsits history only | 10 open or running | phase 3since Jun 20, 2014 | Jun 20, 2014 | none ahead |
| Mundipharmaits history only | 10 open or running | phase 3since Feb 20, 2017 | Feb 20, 2017 | none ahead |
| X-pert Medits history only | 10 open or running | phase 1since Nov 9, 2009 | Nov 9, 2009 | none ahead |
Also a collaborator on its studies: AstraZeneca.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Leidos Life Sciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 7, 2021First studies: 3 phase 2 studies in COVID-19First studyNCT05085574, NCT05077969, NCT05077332
TargetBeta
“Cyclooxygenase-2 inhibitor”ChEMBL 37, by rule
Other programs on PTGS2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| Meloxicamrule | Boehringer Ingelheim | phase 4 | 67 |
| Etoricoxibrule | Organon | phase 4 | 35 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
All 3 Leidos Life Sciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05085574COVID-19 | 2 | Withdrawn | Feb 7, 2023 | 0 |
| NCT05077969COVID-19 · United States | 2 | Terminated | Jun 28, 2022 | 4 |
| NCT05077332COVID-19 · United States | 2 | Completed | Nov 10, 2025 | 4 |
How it is read
Names in the registry
- “Celecoxib”, 49 entries
- “celecoxib”, 7 entries
- “Celecoxib 200mg”, 3 entries
- “Celecoxib + Acetaminophen”, 2 entries
- “Comparator: celecoxib”, 2 entries
Codes read as this program: DFN15.
Conditions, from the studies’ own filings
- Osteoarthritis, 8 studies
- Osteoarthritis, Knee, 8 studies
- Low Back Pain, 5 studies
- Migraine Disorders, 4 studies
- Pain, Postoperative, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.